ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Milestone Pharmaceuticals Inc.
- Target Recruit Count
- 750
- Registration Number
- NCT06716021
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Milestone Pharmaceuticals Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05763953
- Locations
- 🇨🇦
The University of British Columbia, Vancouver, Canada
🇪🇸Hospital Sant Joan de Déu, Barcelona, Spain
🇩🇪Universitätsmedizin Göttingen, Klinik für Pädiatrische Kardiologie, Intensivmedizin und Neonatologie, Göttingen, Germany
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
- Conditions
- Paroxysmal Supraventricular Tachycardia
- Interventions
- Drug: Etripamil NS 70 mgDevice: Aptar Pharma Nasal Spray Bidose System
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Milestone Pharmaceuticals Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT04952610
- Locations
- 🇺🇸
Site # 1025, West Des Moines, Iowa, United States
🇨🇦Site # 0205, Montreal, Quebec, Canada
🇨🇦Site # 0203, Montréal, Quebec, Canada
ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Milestone Pharmaceuticals Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT04467905
- Locations
- 🇳🇱
Treant Zorggroep, Emmen, Netherlands
🇳🇱Jeroen Bosch Ziekenhuis Rijnstate Ziekenhuis, Arnhem, Netherlands
🇳🇱Slingeland Ziekenhuis, Doetinchem, Netherlands
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Milestone Pharmaceuticals Inc.
- Target Recruit Count
- 1116
- Registration Number
- NCT04072835
- Locations
- 🇺🇸
1123, Corvallis, Oregon, United States
🇺🇸105, Yardley, Pennsylvania, United States
🇺🇸1035, Stanford, California, United States
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
- Conditions
- Paroxysmal Supraventricular Tachycardia
- Interventions
- Drug: Etripamil NS 70 mgDevice: Aptar Pharma Nasal Spray Bidose System
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Milestone Pharmaceuticals Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT03635996
- Locations
- 🇺🇸
Piedmont Heart Institute, Atlanta, Georgia, United States
🇺🇸Iowa Heart Center, West Des Moines, Iowa, United States
🇺🇸Los Alamitos Cardiovascular, Los Alamitos, California, United States
Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
- Conditions
- Paroxysmal Supraventricular Tachycardia
- Interventions
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Milestone Pharmaceuticals Inc.
- Target Recruit Count
- 1097
- Registration Number
- NCT03464019
- Locations
- 🇺🇸
Cardiology Associates of Fairfield County, Norwalk, Connecticut, United States
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
🇺🇸The Ohio State University (OSU) Wexner Medical Center, Columbus, Ohio, United States
The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.
- Conditions
- Paroxysmal Supraventricular Tachycardia (PSVT)
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Milestone Pharmaceuticals Inc.
- Target Recruit Count
- 354
- Registration Number
- NCT03353610
- Locations
- 🇺🇸
MAPI, Lexington, Kentucky, United States
Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
- Conditions
- Paroxysmal Supraventricular Tachycardia (PSVT)
- Interventions
- Drug: PlaceboDrug: Etripamil
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Milestone Pharmaceuticals Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT02296190
- Locations
- 🇨🇦
Sunnybrook Health Sciences Center, Toronto, Ontario, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
🇺🇸Great Lakes Medical Research, LLC, Willoughby, Ohio, United States